Could Rich Pharmaceuticals Inc Lose its Strength? The Stock Reaches 52-Week High

 Could Rich Pharmaceuticals Inc Lose its Strength? The Stock Reaches 52 Week High

The stock of Rich Pharmaceuticals Inc (OTCMKTS:RCHA) hit a new 52-week high and has GBX 0.00 target or 6.00% above today’s GBX 0.00 share price. The 5 months bullish chart indicates low risk for the GBX 209,460 company. The 1-year high was reported on Nov, 25 by Barchart.com. If the GBX 0.00 price target is reached, the company will be worth GBX 12,568 more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 89.70M shares traded hands or 158.20% up from the average. Rich Pharmaceuticals Inc (OTCMKTS:RCHA) has declined 80.00% since April 28, 2016 and is downtrending. It has underperformed by 85.41% the S&P500.

More notable recent Rich Pharmaceuticals Inc (OTCMKTS:RCHA) news were published by: Prnewswire.com which released: “Rich Pharmaceuticals, Inc. Announces Quarterly Milestones” on September 27, 2016, also Prnewswire.com with their article: “Rich Pharmaceuticals, Inc. Announces Reverse Split” published on February 10, 2016, Prnewswire.com published: “Rich Pharmaceuticals, Inc. Highlights Goals and Objectives for 2016” on February 16, 2016. More interesting news about Rich Pharmaceuticals Inc (OTCMKTS:RCHA) were released by: Seekingalpha.com and their article: “Rich Pharmaceuticals: Why This Illegal Spam Promotion Could Be Set To Drop” published on April 11, 2014 as well as Prnewswire.com‘s news article titled: “Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage …” with publication date: April 04, 2016.

Rich Pharmaceuticals, Inc. is a development-stage company. The company has a market cap of $209,460. The Firm is a biopharmaceutical firm focused on developing and commercializing therapies in oncology. It currently has negative earnings. The Firm is developing 12-O-tetradecanoylphorbol-13-acetate for the treatment of Hodgkin’s lymphoma (HL), Acute Myelogenous Leukemia (AML) and to cause elevation of white blood cells in patients depleted of these elements due to various conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment